Skip to main content
Lydia Visser
PhD

My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
Published in: International Journal of Molecular Sciences
The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities for less toxic and more targeted treatment options. In this respect, the anti-apoptotic pathway is an attractive target since Hodgkin tumor cells abundantly express components of this pathway. We measured the effect of BH3 mimetics that interfere with anti-apoptotic proteins in cell lines, also in combination with the standard of care chemotherapeutic doxorubicin and the recently discovered preclinically...
Myra Langendonk, Nienke A.M. Smit, Wouter Plattel, Arjan Diepstra, Tom van Meerten, Lydia Visser
Site-Directed Mutants of Parasporin PS2Aa1 with Enhanced Cytotoxic Activity in Colorectal Cancer Cell Lines
Published in: Molecules (Basel, Switzerland)
Parasporin 2 has cytotoxic effects against numerous colon cancer cell lines, making it a viable alternative to traditional treatments. However, its mechanism of action and receptors remain unknown. In this study, site-directed mutagenesis was used to obtain PS2Aa1 mutants with variation in domain I at positions 256 and 257. Variants 015, 002, 3-3, 3-35, and 3-45 presented G256A, G256E, G257A, G257V, and G257E substitutions, respectively. Cytotoxicity tests were performed for the cell viability of cell lines SW480, SW620, and CaCo-2. Mutants 3-3, 3-35, and 3-45 efficiently killed the...
Miguel O. Suárez-Barrera, Lydia Visser, Efraín H. Pinzón-Reyes, Paola Rondón Villarreal, Juan S. Alarcón-Aldana, Nohora Juliana Rueda-Forero
Discovery of Small-Molecule Allosteric Inhibitors of PfATC as Antimalarials
Published in: Journal of the American Chemical Society
The discovery and development of new drugs against malaria remain urgent. Aspartate transcarbamoylase (ATC) has been suggested to be a promising target for antimalarial drug development. Here, we describe a series of small-molecule inhibitors of P. falciparum ATC with low nanomolar binding affinities that selectively bind to a previously unreported allosteric pocket, thereby inhibiting ATC activation. We demonstrate that the buried allosteric pocket is located close to the traditional ATC active site and that reported compounds maintain the active site of PfATC in its low substrate affinity/low activity...
Chao Wang, Bidong Zhang, Arne Krüger, Xiaochen Du, Lydia Visser, Alex Dömling, Carsten Wrenger, Matthew Groves
Cytochrome P450 27C1 Level Dictates Lung Cancer Tumorigenicity and Sensitivity towards Multiple Anticancer Agents and Its Potential Interplay with the IGF-1R/Akt/p53 Signaling Pathway
Published in: International Journal of Molecular Sciences
Cytochrome P450 enzymes (CYP450s) exert mighty catalytic actions in cellular metabolism and detoxication, which play pivotal roles in cell fate determination. Preliminary data shows differential expression levels of CYP27C1, one of the “orphan P450s” in human lung cancer cell lines. Here, we study the functions of CYP27C1 in lung cancer progression and drug endurance, and explore its potential to be a diagnostic and therapeutic target for lung cancer management. Quantitative real-time PCR and immunoblot assays were conducted to estimate the transcription and protein expression level of CYP27C1 in...
Hai-Ying Mo, Qi-Yao Wei, Qiu-Hua Zhong, Xiao-Yun Zhao, Dan Guo, Jin Han, Wachiraporn Noracharttiyapot, Lydia Visser, Anke van den Berg, Yan-Ming Xu, Andy T Y Lau
Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus
Published in: Cancers
Simple Summary: Barrett’s esophagus (BE) is the precursor of esophageal adenocarcinoma (EAC). Dysplastic BE (DBE), including low-grade dysplasia (LGD) and high-grade dysplasia (HGD), shows a higher progression risk to EAC compared to non-dysplastic BE (NDBE). If LGD or HGD is detected, more intensive endoscopic surveillance or endoscopic treatment is recommended. This results in a significantly improved prognosis compared to EACs treated by surgery and/or chemoradiotherapy. However, the miss rates for detecting DBE by endoscopy remain high. Fluorescence molecular endoscopy (FME) can fill this gap by targeting the tumor-specific...
Xiaojuan Zhao, Ruben Y. Gabriels, Wouter T. R. Hooghiemstra, Marjory Koller, Gert Jan Meersma, Manon Buist-Homan, Lydia Visser, Dominic J. Robinson, Anna Tenditnaya, Dimitris Gorpas, Vasilis Ntziachristos, Arend Karrenbeld, Gursah Kats-Ugurlu, Rudolf S. N. Fehrmann, Wouter B. Nagengast